Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Inotiv, Inc. (NOTV)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.81+0.21 (+2.19%)
At close: 04:00PM EDT
9.81 0.00 (0.00%)
After hours: 04:02PM EDT
Advertisement

Inotiv, Inc.

2701 Kent Avenue
West Lafayette, IN 47906
United States
765 463 4527
https://www.inotivco.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees2,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert W. Leasure Jr.Pres, CEO & Director797.4kN/A1960
Ms. Beth A. Taylor CPAVP of Fin. & CFO337.83kN/A1965
Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D.Chief Strategy Officer & Director386.9kN/A1965
Dr. Peter T. KissingerFounder, Chairman Emeritus & Scientific AdvisorN/AN/A1945
Mr. Mo DastagirChief Technology OfficerN/AN/A1977
Ms. Kimberly BeatySr. Director of MarketingN/AN/AN/A
Mr. William D. PitchfordChief HR OfficerN/AN/A1955
Mr. Philip A. DowningSr. VP of Nonclinical ServicesN/AN/A1970
Dr. J. Scott Daniels Ph.D.Sr. VP of DMPKN/AN/AN/A
Mr. John Gregory Beattie DSAChief Operating Officer of Discovery and Safety AssessmentN/AN/A1967
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Corporate Governance

Inotiv, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement